When the listing for 15-month results appeared I was pleasantly surprised. I did not expect Part B results every 3 months. I don't know how to take its retraction, but put very little meaning in it.
And yes, the recent "S1 dual role" paper was for researchers, and furthermore was not focused on our compounds. Would have been great if it showed that our compounds were strong agonists. Medicine is tricky. 2-73's relative efficacy (relative, for example, to donepezil) is not supported by this paper. However nor is it disproven. There are dosing factors, bioavailability, selectivity, etc etc. It is in
human clinical trials where the rubber meets the road. A drug is ultimately measured, just like any scientific theory or mechanical tool or philosophical proposition, by its usefulness.
Market Data 
Markets 
AI
